Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Particulate matter causes inflammation in hair cells, potentially harming hair growth.

IL-15 helps hair grow longer and stronger by extending the growth phase and reducing cell death.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

More precise, personalized therapies are needed for autoimmune diseases.

SARS-CoV-2 proteins help the virus avoid the immune system, delaying response and increasing inflammation.

Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.

Low-dose bisphenol A increases prostate size in rats by affecting certain enzymes.

Similar treatments might work for different types of scarring hair loss.

In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

New treatments for severe alopecia areata show promise but lack standard approval.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Tofacitinib is effective and safe for treating severe alopecia areata.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.

Upadacitinib may cause hair loss.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.